Humacyte, Inc. (NASDAQ:HUMA) Given Average Rating of “Buy” by Brokerages

Humacyte, Inc. (NASDAQ:HUMA) has earned a consensus rating of “Buy” from the six analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $8.60.

HUMA has been the topic of several recent analyst reports. BTIG Research upped their price objective on shares of Humacyte from $8.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, July 15th. EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Benchmark restated a “buy” rating and set a $15.00 price target on shares of Humacyte in a research report on Thursday, September 5th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 price objective on shares of Humacyte in a report on Tuesday, July 2nd.

Humacyte Stock Performance

Shares of Humacyte stock opened at $5.28 on Tuesday. The firm has a market cap of $628.76 million, a PE ratio of -5.28 and a beta of 1.47. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.61. Humacyte has a 52 week low of $1.96 and a 52 week high of $9.97. The business’s fifty day simple moving average is $6.93 and its 200-day simple moving average is $5.56.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Equities analysts forecast that Humacyte will post -1.09 earnings per share for the current year.

Insider Activity at Humacyte

In other Humacyte news, Director Brady W. Dougan sold 252,676 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the completion of the transaction, the director now owns 4,306,464 shares in the company, valued at approximately $28,896,373.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Laura E. Niklason sold 277,090 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $6.47, for a total value of $1,792,772.30. Following the completion of the transaction, the chief executive officer now directly owns 4,029,374 shares of the company’s stock, valued at $26,070,049.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Brady W. Dougan sold 252,676 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the sale, the director now directly owns 4,306,464 shares in the company, valued at approximately $28,896,373.44. The disclosure for this sale can be found here. Insiders have sold a total of 1,084,153 shares of company stock valued at $6,869,996 over the last 90 days. 23.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of HUMA. Endowment Wealth Management Inc. lifted its holdings in shares of Humacyte by 3.1% in the 2nd quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company’s stock valued at $482,000 after purchasing an additional 3,000 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of Humacyte in the second quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. grew its position in shares of Humacyte by 65.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 19,883 shares of the company’s stock worth $62,000 after acquiring an additional 7,897 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Humacyte by 32.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock valued at $168,000 after acquiring an additional 8,557 shares during the period. Finally, Victory Capital Management Inc. purchased a new stake in Humacyte in the 4th quarter valued at $29,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.